Opvee Patent Expiration

Opvee is a drug owned by Indivior Inc. It is protected by 1 US drug patent filed in 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 10, 2038. Details of Opvee's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11458091 Compositions and methods for the treatment of opioid overdose
Jul, 2038

(13 years from now)

Active


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Opvee's patents.

Given below is the list of recent legal activities going on the following patents of Opvee.

Activity Date Patent Number
Patent litigations
Post Issue Communication - Certificate of Correction 13 Jul, 2023 US11458091
Recordation of Patent Grant Mailed 04 Oct, 2022 US11458091
Patent Issue Date Used in PTA Calculation 04 Oct, 2022 US11458091
Email Notification 15 Sep, 2022 US11458091
Issue Notification Mailed 14 Sep, 2022 US11458091
Dispatch to FDC 08 Sep, 2022 US11458091
Application Is Considered Ready for Issue 08 Sep, 2022 US11458091
Email Notification 31 Aug, 2022 US11458091
Mailing Corrected Notice of Allowability 31 Aug, 2022 US11458091
Corrected Notice of Allowability 26 Aug, 2022 US11458091


FDA has granted several exclusivities to Opvee. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Opvee, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Opvee.

Exclusivity Information

Opvee holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2026. Details of Opvee's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 22, 2026

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Opvee is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Opvee's family patents as well as insights into ongoing legal events on those patents.

Opvee's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Opvee's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jul 10, 2038 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Opvee Generics:

Nalmefene Hydrochloride is the generic name for the brand Opvee. 2 different companies have already filed for the generic of Opvee, with Chengdu Shuode having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Opvee's generic

Alternative Brands for Opvee

Opvee which is used for reversing opioid overdose., has several other brand drugs using the same active ingredient (Nalmefene Hydrochloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Purdue Pharma Lp
Zurnai (autoinjector)


Apart from brand drugs containing the same ingredient, some generics have also been filed for Nalmefene Hydrochloride, Opvee's active ingredient. Check the complete list of approved generic manufacturers for Opvee





About Opvee

Opvee is a drug owned by Indivior Inc. It is used for reversing opioid overdose. Opvee uses Nalmefene Hydrochloride as an active ingredient. Opvee was launched by Indivior in 2023.

Approval Date:

Opvee was approved by FDA for market use on 22 May, 2023.

Active Ingredient:

Opvee uses Nalmefene Hydrochloride as the active ingredient. Check out other Drugs and Companies using Nalmefene Hydrochloride ingredient

Treatment:

Opvee is used for reversing opioid overdose.

Dosage:

Opvee is available in spray form for nasal use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
EQ 2.7MG BASE/SPRAY SPRAY Prescription NASAL